Article
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity

https://doi.org/10.1016/j.xcrm.2020.100188Get rights and content
Under a Creative Commons license
open access

Highlights

  • Brachyury defines the chordoma super-enhancer landscape

  • Brachyury autoregulates through a transcriptional condensate

  • CDK7/12/13i and brachyury degradation target the brachyury transcriptional condensate

  • Brachyury degradation inhibits chordoma identity genes and induces senescence

Summary

Chordomas are rare spinal tumors addicted to expression of the developmental transcription factor brachyury. In chordomas, brachyury is super-enhancer associated and preferentially downregulated by pharmacologic transcriptional CDK inhibition, leading to cell death. To understand the underlying basis of this sensitivity, we dissect the brachyury transcription regulatory network and compare the consequences of brachyury degradation with transcriptional CDK inhibition. Brachyury defines the chordoma super-enhancer landscape and autoregulates through binding its super-enhancer, and its locus forms a transcriptional condensate. Transcriptional CDK inhibition and brachyury degradation disrupt brachyury autoregulation, leading to loss of its transcriptional condensate and transcriptional program. Compared with transcriptional CDK inhibition, which globally downregulates transcription, leading to cell death, brachyury degradation is much more selective, inducing senescence and sensitizing cells to anti-apoptotic inhibition. These data suggest that brachyury downregulation is a core tenet of transcriptional CDK inhibition and motivates developing strategies to target brachyury and its autoregulatory feedback loop.

Keywords

chordoma
phase separation
transcription
transcription factor
transcriptional inhibition
targeted degradation
brachyury
super-enhancer
cyclin-dependent kinase
transcriptional condensate

Cited by (0)

13

Present address: Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK

14

Present address: Shared Resources, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

15

Present address: Kronos Bio, Cambridge, MA 02139, USA

16

Lead contact